



Original Article

In Vitro Antibacterial Activity of a Compound Isolated from *Astilbe rivularis* Buch.–Ham. Ex D.Don Leaves

Tanaya Ghosh¹, Prasenjit Mitra², Prasanta Kumar Mitra^{1,*}

¹Department of Medical Biotechnology, Sikkim Manipal University, SMIMS, Sikkim, India.

²Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

ARTICLE INFO

A B S T R A C T

Received: 15 Apr 2018
Accepted: 26 Apr 2018

Astilbe rivularis Buch. – Ham. Ex D. Don (*A. rivularis*), one of the medicinal plants of North East Himalayan region of India, has several pharmacological activities including anti bacterial property. In the present study we have isolated a compound from *A. rivularis* leaves. In vitro anti bacterial property of the isolated compound was studied against four Gram - positive bacteria viz. *Staphylococcus aureus*, *Bacillus megaterium*, *Bacillus subtilis* and *Streptococcus pyogenes* and four Gram- negative bacteria like *Shigella dysenteriae*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Salmonella typhi*. Disc diffusion technique was used for in vitro antibacterial screening. Result showed that the isolated compound exerted anti bacterial activity against all bacteria used but the antibacterial activity was more in Gram - positive bacteria than in Gram - negative bacteria. Highest activity was noted against *Bacillus subtilis* and lowest activity was found for *Salmonella typhi*. The MIC (minimum inhibitory concentration) values of the compound isolated from the leaves of *A. rivularis* against the bacteria ranged from 4 – 64 microgram/mL. Results were comparable to that of standard antibiotic kanamycin suggesting thereby that the isolated compound had good in vitro anti bacterial activity against the tested bacteria, therefore, provides a scientific rationale for its use as anti bacterial agent in future.

Keywords: *A. rivularis*, Isolation of a compound, anti bacterial property, Disc diffusion technique, Zone of inhibition, Minimum inhibitory concentration

1. INTRODUCTION

Astilbe rivularis, Buch. Due to indiscriminate use of antibiotics in the treatment of infectious diseases, microorganisms developed resistance to many antibiotics¹. While *Streptococcus pneumoniae* was found resistant against penicillin, strains of *Streptococcus pyogenes* resistant to antibiotic macrolide have emerged². *Enterococcus faecalis* and *Enterococcus faecium* developed multidrug resistance³. Penicillin resistant

Corresponding author *

Dr. Prasanta Kumar Mitra,
Prof. & Head, Dept. of Medical Biotechnology,
Sikkim Manipal Institute of Medical Sciences,
Sikkim Manipal University
Gangtok : 737102, Sikkim, India, Phone: +91 9434063026
Email: dr_pkmitra@rediffmail.com

Staphylococcus aureus was found in 1947. Methicillin-resistant *S. aureus* (MRSA) is now quite common in hospitals. Today, half of all *S. aureus* infections in the United States of America are resistant to penicillin, tetracycline, methicillin, vancomycin and erythromycin⁴.

In the year 2004 multidrug resistant *Acinetobacter baumannii* (MRAB) with a few isolates resistant to all drugs tested were discovered⁵. *Klebsiella pneumoniae* developed resistance even carbapenem⁶. *Clostridium difficile* strains resistant to clindamycin as well as fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin were also reported^{7,8}. *Mycobacterium tuberculosis* was once sensitive to streptomycin developed resistance to streptomycin⁹. Likewise *Neisseria gonorrhoeae*, once killed by penicillin developed resistance against penicillin¹⁰. Strains of *N. gonorrhoea* have been found to be resistant to third-generation antibiotic cephalosporins, fluoroquinolones, tetracyclines and aminoglycosides¹¹. *Pseudomonas aeruginosa*, strains of *Salmonella* and *Escherichia coli* also developed resistance against various antibiotics¹².

Antibiotic resistance is, therefore, a worldwide public health problem today and has created immense concern in treatment of infectious diseases¹³. To combat the situation continuous effort is going on for synthesis of new chemicals having antimicrobial activity¹⁴. Lot of chemical compounds are synthesized, their anti bacterial activity is established. Unfortunately, most of these compounds are potentially toxic and are not free from side effects on the host¹⁵. This has extended the research even in the field of medicinal plants for isolation of natural compounds which will be less toxic and a proper substitute of chemical antimicrobial agents¹⁶.

Astilbe rivularis, Buch. – Ham. Ex D. Don (*A. rivularis*), family – Saxifragaceae, a tall herb stem and leaves are covered with hairs, is one of the medicinal plants of North Eastern Himalaya¹⁷. The plant, distributed at a range of 5000 – 9000 feet in Common Temperate of Himalaya and found on sloppy waste place has different names. In Lepcha it is called Pango and in Nepali the plant is known as Buriokahti¹⁸. Traditional use of the plant is in curing dysentery, headache, hemorrhages, diarrhoea, prolapse of uterus and to improve fertility¹⁹. The plant has anti microbial²⁰, anti viral²¹, anti peptic ulcer²² and anti oxidant activity²³. During phytochemical investigation compounds like flavonoids, terpenoids and bergenin. 11-O-galloylbergenin, catechin, afzelechin, epiafzelechin and 2-(D-glucopyranosyloxy)-4-hydroxybenzenacetonitrile were isolated from the plant²⁴. Methanol extract of *A. rivularis* of Nepal has highest anti bacterial activity against *Klebsiella pneumoniae*²⁵. Recently we confirmed in vitro anti bacterial activity of methanol extract of *A. rivularis* grown in North East Himalayan region of India and noted maximum anti bacterial activity during the months of July and August (paper is under communication). Aim of the present work was to isolate the anti bacterial compound present in *A.*

rivularis leaves and to study its anti bacterial activity against number of Gram positive and Gram negative bacteria.

2. METHODOLOGY

2.1 Collection of plant materials

A. rivularis leaves were collected from the medicinal plants garden of the University of North Bengal, Siliguri (26°41'30.9984" N, 88°27'4.5756" E, elevation, 410 ft), Dist. Darjeeling, West Bengal. Leaves were collected in between 9 and 10 AM during the months of July and August as we have noted earlier that this is the time when the plant has maximum anti bacterial activity (paper is under communication). Leaves were authenticated by the experts of the department of Botany of the said University. A voucher specimen was kept in the department of department of Biochemistry, North Bengal Medical College, Siliguri, West Bengal, India for future references. Leaves were thoroughly washed, shade dried and powdered. The powder was used for isolation work.



Fig 1: *Astilbe rivularis* Buch. – Ham. Ex D. Don

2.2 Isolation work

This was done by the following scheme. Principles of standard isolation procedures of chemical compounds from plant sources were followed²⁶⁻²⁹

2.3 Chemicals

Chemicals required for the study were purchased from Loba Chem. Lab, Himedia Lab, India and from Merck, Germany

2.4 Bacteria

Four Gram - positive bacteria viz. *Bacillus subtilis*, *Bacillus megaterium*, *Staphylococcus aureus* and *Streptococcus pyogenes* and four Gram-negative bacteria viz. *Pseudomonas aeruginosa*, *Shigella dysenteriae*, *Escherichia coli* and *Salmonella typhi* were employed to determine antibacterial activity and minimum inhibitory concentration. All these bacteria were collected from the department of Microbiology, North Bengal Medical College Hospital, Siliguri, West Bengal.

2.5 Media

Nutrient agar media (Difco laboratories) pH 7.2 and nutrient broth media (Difco laboratories) pH 6.8 were used for antibacterial screening and minimum inhibitory concentration determination.

2.6 Antibacterial screening

In vitro antibacterial screening was carried out by disc diffusion method³⁰. According to this method, 20 ml quantities of nutrient agar were placed in a petri dish with 0.1 ml of 10⁻² dilution of bacterial culture of 20 hours old. Filter paper discs (6 mm diameter) impregnated with 40 µg per disc concentration of the compound isolated from *A. rivularis* leaves were placed on test bacteria-seeded plates. Blank disc impregnated with water was used as negative control. Zone of inhibition was recorded after 18 hours of incubation. Diameters of zone of inhibition produced by the solution prepared from *A. rivularis* were compared with that of standard antibiotic kanamycin 40 µg per disc. Each sample was used for five times for the determination of anti bacterial activity.

2.7 Minimum inhibitory concentration (MIC) determination

Minimum inhibitory concentration is defined as the lowest concentration of antibiotic completely inhibiting visible growth of bacteria after 18 – 24 hours of incubation at 37 °C. This was done by the method of Mosaddik and Haque³¹. According to this method, compound isolated from *A. rivularis* (1.0 mg) was dissolved in 2 ml nutrient broth media to obtain a stock solution of concentration 500 µg/ml. 3 drops of Tween 80 was added in nutrient broth to facilitate dissolution. Serial dilution technique was followed to obtain 250 µg/ml concentration of the compound. One drop (0.02ml) of prepared suspensions of organism (10⁶ organism/ml) was added to each broth dilution. These dilutions were then incubated for 20 hours at 37°C. Growth of bacteria was examined by noting turbidity of the solution. The nutrient broth media with 3 drops of Tween 80 was used as negative control while kanamycin was used as positive control.

2.8 Statistical analysis

The values were expressed as mean ± SEM and were analyzed using one-way analysis of variance (ANOVA) using Statistical Package for Social Sciences (SPSS) 20th versions. Differences between means were tested employing Duncan's multiple comparison test and significance was set at p < 0.05.

2.9 Diagrammatic scheme for isolation of a compound from leaves of *A. rivularis*.

Powdered leaves of *A. rivularis* (50 g)

SOLVENT EXTRACTION

Extracted with 500 ml of methanol in soxhlet at 37°C for 15 minutes. It was then centrifuged. Supernatant collected and evaporated to dryness.

Active brown mass

ACID REFLUX

Refluxed with 50 ml of 1(N) HCl for 10 min on a water bath at 100 °C. It was then cooled and centrifuged. Supernatant was evaporated to dryness.

Active brown mass

TREATMENT WITH ETHYL ACETATE

Extracted with 50 ml ethyl acetate on a rotary shaker for 15 min. It was then centrifuged. Supernatant was evaporated to dryness.

Active brown mass

ALUMINA COLUMN CHROMATOGRAPHY

Extracted with 10 ml methanol for 5 min. It was then filtered. With filtrate alumina column chromatography was performed. Elution was done by methanol – ethyl acetate mixture (1:1 v/v).

Fourth band was found active

SILICA GEL G CHROMATOGRAPHY

Eluent of active fourth band was evaporated to dryness. The dry mass was extracted with 15 ml methanol for 5 min. It was then filtered. With filtrate silica gel G column chromatography was done. Elution was done by chloroform : methanol mixture (1:1 v/v).

Second band was active

POLYAMIDE COLUMN CHROMATOGRAPHY

Eluent of active second band was evaporated to dryness. The dry mass was extracted with 10 ml methanol for 5 min. It was then filtered and the filtrate was subjected to column chromatography using polyamide as adsorbent. Elution was done by methanol, acetone mixture (1:1 v/v).

First band was found active

CRYSTALLIZATION

Eluent of the active first band obtained from the above step was evaporated to dryness. Repeated crystallization was done from chloroform ethyl acetate (40:60, v/v) mixture.

Crystals obtained (5.8 mg)

3. RESULTS

3.1 Isolation of compound

A compound was isolated from the leaves of *A. rivularis*.

3.2 Anti bacterial activity of the isolated compound

Results of disc diffusion method (Table – 1) indicated that the isolated compound from *A. rivularis* leaves at 40 µg per disc concentrations exerted anti bacterial activity against all four Gram positive bacteria viz. *Bacillus subtilis*, *Bacillus megaterium*, *Staphylococcus aureus* and *Streptococcus pyogenes* and four Gram-negative bacteria viz. *Pseudomonas aeruginosa*, *Shigella dysenteriae*, *Escherichia coli* and *Salmonella typhi*. Activity was comparable to that of reference drug kanamycin in 40µg per disc concentration. Antibacterial activity of the isolated compound was more in Gram - positive bacteria than in Gram - negative bacteria. Highest activity was noted against *Bacillus subtilis* for Gram positive bacteria and *Escherichia coli* for Gram-negative bacteria. Lowest anti bacterial activity of the isolated compound, however, was noted against *Streptococcus Pyogenes* and *Salmonella typhi* for Gram positive and Gram-negative bacteria respectively.

Table – 2 shows results of minimum inhibitory concentration of the isolated compound from *A. rivularis* leaves and kanamycin against the said Gram positive and Gram negative bacteria . The MIC (Minimum Inhibitory Concentration) of the isolated compound ranged from 4 to 16 for Gram positive bacteria and 8 to 64 microgram/mL for Gram negative bacteria respectively. For kanamycin MIC value for Gram positive bacteria was found to vary between 2 and 8 and for Gram negative bacteria it came between 4 and 16.

Table 1: *In vitro* antibacterial activity of the isolated compound from *A. rivularis* leaves and kanamycin [Zone of inhibition (diameter in mm)] against Gram positive and Gram negative bacteria.

Bacteria	Strain	Compound isolated from <i>A. rivularis</i> leaves (40 µg per disc)	Kanamycin (40 µg per disc)
Gram – positive			
<i>Bacillus subtilis</i>	ATCC 19659	34 ± 0.3*	38 ± 0.5
<i>Bacillus megaterium</i>	NBMC 1122	30 ± 0.2	34 ± 0.6
<i>Staphylococcus aureus</i>	ATCC 25923	28 ± 0.3	30 ± 0.4
<i>Streptococcus pyogenes</i>	NBMC 1321	24 ± 0.2	28 ± 0.3
Gram – negative			
<i>Escherichia coli</i>	ATCC 25922	25 ± 0.3*	28 ± 0.7
<i>Shigelladysenteriae</i>	NBMC 1127	21 ± 0.2	24 ± 0.6
<i>Pseudomonas aeruginosa</i>	NBMC 1243	20 ± 0.5	23 ± 0.6
<i>Salmonella typhi</i>	MTCC 733	19 ± 0.4	22 ± 1.0

Data was in mean SEM (n = 5). Control was made with water. It had no zone of inhibition. So data has not been shown.* Significanttp<0.01

4. DISCUSSION

Anti bacterial compounds have been isolated from medicinal plants.

Table 2 : Minimum inhibitory concentration of the isolated compound from *A. Rivularis* leaves and kanamycin against Gram positive and Gram negative bacteria

Bacteria	MIC values of the compound isolated from <i>A. rivularis</i> leaves (microgram/mL)	MIC values of kanamycin (microgram/mL)
Gram – positive		
<i>Bacillus subtilis</i>	4	2
<i>Bacillus megaterium</i>	8	4
<i>Staphylococcus aureus</i>	8	4
<i>Streptococcus pyogenes</i>	16	8
Gram – negative		
<i>Escherichia coli</i>	8	4
<i>Shigelladysenteriae</i>	16	8
<i>Pseudomonas aeruginosa</i>	16	8
<i>Salmonella typhi</i>	64	16

Negative control containing water had no MIC value. Thus, it has not been shown




Fig 1: *In vitro* antibacterial activity of the isolated compound from *A. rivularis* leaves and kanamycin [Zone of inhibition (diameter in mm)] against Gram positive and Gram negative bacteria.

Category 1: *Bacillus subtilis*, Category 2: *Bacillus megaterium*, Category 3: *Staphylococcus aureus*, Category 4: *Streptococcus pyogenes* Category 5: *Escherichia coli* Category 6: *Shigella dysenteriae* Category 7: *Pseudomonas aeruginosa* Category 8: *Salmonella typhi*
Isolated compound Kanamycin




Fig 2: Minimum inhibitory concentration of the isolated compound from *A. Rivularis* leaves and kanamycin against Gram positive and Gram negative bacteria

Category 1: *Bacillus subtilis* Category 2: *Bacillus megaterium*
Category 3: *Staphylococcus aureus* Category 4: *Streptococcus pyogenes*
Category 5: *Escherichia coli* Category 6: *Shigella dysenteriae* Category 7: *Pseudomonas aeruginosa* Category 8: *Salmonella typhi*
Isolated compound Kanamycin

Hyperenone A, hypercalin B and hyperphorin were isolated from different species of the plant genus *Hypericum* (*Hypericum acmosepalum*; *Hypericum olympicum*). Isolated compounds were found responsible for anti bacterial activity on resistant *Staphylococcus aureus* and on *Mycobacterium tuberculosis*^{32,33}. Araujo et al. isolated two compounds viz. xanthone 8-carboxymethyl-1,5,6 trihydroxy 3 methoxyxanthone and 6-hydroxy-7-methoxyluteolin from the leaves of *Leiothrix spiralis*, a South American plant belonging to the Eriocaulaceae family. The compounds showed anti bacterial activity against *Escherichia coli* and *Pseudomonas aeruginosa*³⁴. Catechins and theoflavins of tea extracts have anti bacterial effect against *Bacillus cereus*³⁵. 2',5-di-O-galloyl d-hamamelose, a natural nonpeptide compound isolated from the bark of *Hamamelis virginiana*, was found to inhibit *S. aureus* and *S. epidermidis*³⁶. 3,5,4'-trihydroxystilbe isolated from grapes and other plants showed direct antibacterial activity against *Neisseria gonorrhoeae*

Int J Pharma Res Health Sci. 2018; 6 (2): 2491–96
and *Neisseria meningitides*³⁷. Kadota et al. isolated trichorabdal from *Rabdosia trichocarpa* and noted its anti bacterial effect against *Helicobacter pylori*³⁸. Alkaloid berberine, isolated from *Mahonia aquifolia*, could in activate *Plasmodium* Trypanosomes³⁹.

In the present study by solvent extraction, acid hydrolysis, solvent treatment and chromatographic experiments we have isolated a compound from *A. rivularis* leaves. The compound showed in vitro anti bacterial activity against four Gram positive bacteria viz. *Bacillus subtilis*, *Bacillus megaterium*, *Staphylococcus aureus* and *Streptococcus pyogenes* and four Gram-negative bacteria viz. *Pseudomonas aeruginosa*, *Shigella dysenteriae*, *Escherichia coli* and *Salmonella typhias* evidenced by disc diffusion technique. Results were comparable to that of standard antibiotic kanamycin (Figure – 1). The MIC (minimum inhibitory concentration) value of the compound was also found comparable to that of standard antibiotic kanamycin (Figure – 2). Isolated compound now requires characterization. In isolation process methanol was used as extraction solvent. Compound may, therefore, be anthocyanin, saponin, tannin, terpenoid or polyphenol⁴⁰. Work on characterization of the compound is now going on in our laboratory.

5. CONCLUSION

In this study we have isolated a compound from the leaves of *A. rivularis*. The compound showed anti bacterial activity against four Gram positive and four Gram negative bacteria. Anti bacterial activity of the compound was comparable to that of kanamycin, a standard antibiotic. The isolated compound, therefore, provides a scientific rationale for its use as anti bacterial agent in future.

6. ACKNOWLEDGEMENT

Identification of the leaves of *A. rivularis* by the taxonomists of the department of Botany, University of North Bengal, Siliguri, Dist. Darjeeling, West Bengal is gratefully acknowledged

7. REFERENCES

1. Coates A., Hu Y. and Bax R. The future challenges facing the development of new antimicrobial drugs. Nature Reviewing Drug Discover, 2002;1: 895-910.
2. Albrich W., Monnet D. L. and Harbarth S. Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*. Emerging Infect. Dis. 2004; 10 (3): 514–7.
3. Hidron A.I., Edwards J. R., Patel J., Horan Teresa C., Sievert Dawn M., Pollock Daniel A. and Fridkin Scott K. (2008) Antimicrobial-resistant pathogens associated with healthcare-associated infections. NCHS annual update. 2008; 6: 3 – 7.
4. Bozdogan B. Ü., Esel D., Whitener C., Browne F. A. and Appelbaum P. C. Antibacterial susceptibility of a

- vancomycin-resistant *Staphylococcus aureus* strain isolated at the Hershey Medical Center. Journal of Antimicrobial Chemotherapy, 2003; 52: 864–868.
5. Centers for Disease Control and Prevention (CDC) *Acinetobacter baumannii* infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb. Mortal. Wkly. Rep. 2004; 53 (45): 1063–6.
6. Arnold, Ryan S., Kerri A. Thom, Saarikha Sharma, Phillips Michael, Johnson J. Kristie, Morgan J., and Daniel J. Emergence of *Klebsiella pneumoniae* Carbapenemase-Producing Bacteria. Southern Medical Journal, 2011; 104 : 40–5.
7. Johnson, S., Samore M. H., Farrow K. A., Killgore George E., Tenover Fred C., Lyras Dena, Rood Julian I. and Degirolami Paola. Epidemic of diarrhea caused by a clindamycin-resistant strain of *Clostridium difficile* in four hospitals. New England Journal of Medicine. 1999; 341 (23): 1645–1651.
8. Loo V., Poirier L., Miller M., Oughton Matthew and Libman Michael D. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353 (23): 2442–9.
9. Herzog Basel. History of Tuberculosis. Respiration. 1998; 65 (1): 5–15.
10. Ligon B. Lee., Ludwig Albert and Neisser Sigismund. Discoverer of the Cause of Gonorrhoea. Seminars in Pediatric Infectious Diseases. 2005; 16 (4): 336–341.
11. Centers for Disease Control and Prevention. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections. MMWR. Morbidity and mortality weekly report. 2012; 61 (31): 590–4.
12. Ochiai K., Yamanaka T., Kimura K. and Sawada O. Inheritance of drug resistance (and its transfer) between *Shigella* strains and Between *Shigella* and *E. coli* strains. Hihon Iji Shimpor (in Japanese). 1959; 34 : 1861.
13. Hawkey P.M. The growing burden of antimicrobial resistance. J. Antimicrob. Chemother. 2008; 62 (Suppl 1): 1–9.
14. Baregama L. and Talesara G. L. Synthesis and antimicrobial studies of 3 – alkoxy-5-9p-substituted aryl 10 Biguanidinopentane-2,4dione and related compounds. Rese J Chem Enviro. 2002; 6: 59–62.
15. Geddes A.M. Prescribers' needs for the developed and third world. pp. 231– 242. In: The Scientific basis of antimicrobial chemotherapy. Greenwood, FO, O'Grady. Editors. Vol. I Cambridge. Cambridge University Press. 1985.
16. Pandian M.R., Banu G. S. and Kumar G. A study of the antimicrobial activity of *Alangium salviifolium*. Indian J Pharmacol. 2006; 38: 203–4.

17. Das A. P. and Ghosh Chandra. Germplasm collection in garden of medicinal plants. University of North Bengal, Siliguri, West Bengal, 2009; P. 8.
18. GurungBejoy. The medicinal plants of Sikkim Himalaya. Pub.BejoyGurung, East Sikkim, 2002; P. 55.
19. Manandhar N. P. Plants and people of Nepal. Timber Press, Inc. Oregon, USA, 2002; P.29
20. Adhikary Pratik, Roshan K. C., KayasthaDeepika and Thapa Dinesh. Phytochemical Screening and Anti-Microbial Properties of Medicinal Plants of Dhunkharka Community, Kavrepalanchowk, Nepal International Journal of Pharmaceutical & Biological Archives 2011; 2(6): 1663-1667
21. Rajbhandari Meena, LalkMichael, MentelRenate and Lindequist Ulrike. Antiviral Activity and Constituents of the Nepalese Medicinal Plant *Astilberivularis* Rec. Nat. Prod. 2011; 5(2): 138 -142.
22. Mitra P. and Mitra P. K. Use of *Astilberivularis* Buch. – Ham. Ex D. Don as anti peptic ulcer agent, Pleione, 2008; 2(1): 74 – 76.
23. Mandal Palash, Misra T. K. Remove from marked Records In vitro antioxidant potential of *Astilberivularis* rhizome, Canadian Journal of Pure & Applied Sciences, 2009; 3(1): 649-654.
24. Gyawali R, Dahal B, Gautam R, Shrestha S, Joshi S, Luitel A and Khanal D. Phytochemical studies on traditional medicinal plants of Nepal and their formulations, IJBPAS, 2014; 3(2): 189-203.
25. Adhikary Pratik, Roshan K. C., KayasthaDeepika and Thapa Dinesh. Phytochemical Screening and Anti-Microbial Properties of Medicinal Plants of Dhunkharka Community, Kavrepalanchowk, Nepal International Journal of Pharmaceutical & Biological Archives 2011; 2(6): 1663-1667
26. Cannell RJP. Natural Products Isolation, New Jersey, Human Press Inc 1998; 165-208.
27. Li HB, Jiang Y, Chen F. Separation methods used for *Scutellaria baicalensis* active components, J. Chromatography, 2004; 8(12): 277-290.
28. Huie CW. A review of modern sample-preparation techniques for the extraction and analysis of medicinal plants. Anal. Bioanal. Chem, 2002; 373: 23-30.
29. Sasidharan S, Chen Y, Saravanan D, Sundram KM, Yoga Latha L. Extraction, Isolation and Characterization of Bioactive Compounds from Plants' Extracts. Afr J Trad Complement Altern Med, 2011; 8(1): 1-10.
30. Rahman MM, Mosaddik MA, Wahed MI, Haque ME. Antimicrobial activity and cytotoxicity of *Trapabispinosa*. Fitoterapia, 2000; 71, 704 - 6.
31. Mosaddik MA and Haque ME. Cytotoxicity and antimicrobial activity of goniothalamine isolated from *Bryonopsis laciniata*. Phytother Res., 2003; 17: 1155 - 7.
32. Osman K., Evangelopoulos D., Basavannacharya C. et al. An antibacterial from *Hypericum acmosepalum* inhibits ATP-dependent MurE ligase from *Mycobacterium tuberculosis*. Intern. J. Antimicrob. Agents. 2012; 39: 124-129.
33. Shiu W. K. P., Rahman M. M., Curry J. et al. Antibacterial acylphloroglucinols from *Hypericum olympicum*. J. Nat. Prod. 2012; 75: 336-343.
34. Araujo M. G., Hilario F., Nogueira L. G., Vilegas W., Santos L. C., Bauab T. M. Chemical constituents of the methanolic extract of leaves of *Leiothrix spiralis* Ruhland and their antimicrobial activity. Molecules 16, 10479-10490 (2011).
35. Friedman M., Henika P. R., Levin C. E., Mandrell R. E. and Kozukue N. Antimicrobial Activities of tea catechins and theoflavins and tea extracts against *Bacillus cereus*. J. Food Prot. 2006; 69: 354-361.
36. Pan J. and Ren D. Quorum sensing inhibitors: a patent overview. Expert Opin. Ther. Pat. 2009; 19, 1581-1601.
37. Docherty J. J., Fu M. M. and Tsai M. Resveratrol selectively inhibits *Neisseria gonorrhoeae* and *Neisseria meningitidis*. J. Antimicrob. Chemother. 2001; 47: 243-244.
38. Kadota S, Basnet P, Ishii E, Tamura T, Namba T. Antibacterial activity of trichorabdol from *Rabdosia trichocarpa* against *Helicobacter pylori*. Zentbl. Bakteriologie, 1997; 286: 63-67.
39. Freiburghaus F, Kaminsky R, Nkonya MHH, Brun R. Evaluation of African medicinal plants for their in vitro trypanocidal activity. J. Ethnopharmacol, 1996; 55: 1-11.
40. Cowan Marjorie Murphy. Plant Products as Antimicrobial Agents. Clinical Microbiology Reviews, 1999; 12(4) : 564-582.

Conflict of Interest: None

Source of Funding: Nil